Exclusive Collaboration Between GRIN Therapeutics and Angelini Pharma
GRIN Therapeutics has recently forged a vital partnership with Angelini Pharma, aiming to advance the development and commercialization of radiprodil, a promising investigational therapy designed for neurodevelopmental disorders. This collaboration is set to leverage Angelini Pharma's extensive international influence alongside GRIN's innovative capabilities in precision therapeutic development.
Collaboration Details and Financial Commitment
Under the terms of this exclusive collaboration, GRIN Therapeutics is slated to receive an upfront payment of $50 million from Angelini Pharma. Furthermore, the collaboration opens the door for GRIN to earn up to $520 million in milestone payments, alongside tiered royalties and shared development costs. Importantly, GRIN retains leadership in global development and exclusive rights over radiprodil in the United States, Canada, and Mexico.
Funding for Pivotal Trials
The partnership coincides with the successful completion of GRIN's Series D financing round, which totaled $140 million. This round saw significant investment from Angelini Pharma, which provided a strategic equity investment of $65 million, as well as $75 million from existing investor Blackstone Life Sciences. The combined funding will bolster GRIN's operations, with particular focus on advancing a global pivotal Phase 3 trial set to begin in the near future.
Significance of Radiprodil in Neurodevelopmental Disorders
Radiprodil is classified as a targeted, selective negative allosteric modulator of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor. This receptor plays a crucial role in synaptic transmission, cognitive functions, and seizure activity. Many neurodevelopmental disorders (NDDs) and forms of epilepsy are associated with genetic mutations or the overactivation of NMDA receptors, which highlights the therapeutic potential of radiprodil in this domain.
Strategic Validation through Collaboration
CEO Bruce Leuchter expressed enthusiasm regarding the collaboration, asserting that it validates GRIN's clinical data and the essential role radiprodil could play as the first approved treatment for GRIN-related neurodevelopmental disorders. Both GRIN and Angelini Pharma are positioned to make substantial impacts in addressing the urgent healthcare needs of affected populations.
Ongoing and Future Clinical Developments
Currently, radiprodil is undergoing an open-label Phase 1b/2a study, named the Astroscape trial, which focuses on patients suffering from tuberous sclerosis complex and focal cortical dysplasia type II. Meanwhile, the anticipated global Phase 3 trial of radiprodil for GRIN-NDD will evaluate its effectiveness in addressing key issues such as seizures and behavioral disturbances.
Response from Company Leadership
Both companies acknowledge the importance of their strategic collaboration in enhancing brain health treatments. Angelini Pharma's CEO, Jacopo Andreose, referred to radiprodil as a potential solution for unmet medical needs in pediatric neurological diseases. This partnership aims not only at treatment development but also aims to improve outcomes for families grappling with such challenges.
About GRIN Therapeutics
GRIN Therapeutics is dedicated to pioneering research and developing innovative therapies for pediatric neurodevelopmental disorders. The company aims to provide hope for children and families affected by these conditions. Their commitment to clinical research is underscored by their recent advancements and ongoing trials with radiprodil.
About Angelini Pharma
As a leading international pharmaceutical entity and part of the broader Angelini Industries, Angelini Pharma focuses on creating health solutions that enhance brain health. The organization prides itself on its commitment to research and development, promoting treatments that address mental health and epilepsy.
About Neurvati Neurosciences
Neurvati Neurosciences, linked with GRIN Therapeutics, specializes in developing transformative drug candidates within the neuroscience landscape. Their collaborative approach aims to align resources effectively to challenge existing treatment paradigms and elevate patient care in various neurological and psychiatric disorders.
Frequently Asked Questions
What is the primary goal of the GRIN and Angelini collaboration?
The collaboration aims to develop and commercialize radiprodil for neurodevelopmental disorders globally, enhancing treatment options beyond North America.
How much is GRIN receiving from Angelini Pharma?
GRIN Therapeutics will receive an upfront payment of $50 million as part of their agreement, with additional potential milestone payments.
What is radiprodil's mechanism of action?
Radiprodil acts as a selective negative allosteric modulator of the GluN2B subunit of NMDA receptors, impacting synaptic transmission and seizure control.
What ongoing studies is GRIN conducting with radiprodil?
GRIN is currently conducting the Astroscape trial, evaluating radiprodil's effects on tuberous sclerosis complex and focal cortical dysplasia type II patients.
What are the future plans for radiprodil's development?
GRIN plans to initiate a global pivotal Phase 3 trial for radiprodil focused on GRIN-related neurodevelopmental disorder.
